Shock wave therapy for patellar tendinitis with or without a coordinated fascial center-point treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a randomized controlled trial that assigns eligible adults with patellar tendinitis to receive either extracorporeal shock wave therapy (ESWT) to the patellar tendon alone or ESWT to the patellar tendon combined with a coordinated fascial center-point application. Randomization was done using a random number table and treatments were delivered by an experienced rehabilitation therapist. Outcomes measured at baseline and the day after completing treatment include pain (Visual Analogue Scale), knee function (Lysholm Knee Scoring System), and patellar tendon thickness by imaging. The protocol focuses on short-term changes immediately after the treatment course.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Adults aged between 18 and 45 yearsWillingness to sign an informed consent form and ability to cooperate with the treatment and follow-up aspects of this study.
2. Meeting the diagnostic criteria for patellar tendinitis as outlined in "Practical Sports Medicine" (2023 edition)
3. Knee joint pain with a VAS score of ≥3 and ≤7
4. No other orthopedic or neurological conditions that could affect lower limb strength or mobility
5. Willingness to sign an informed consent form and ability to cooperate with the treatment and follow-up aspects of this study

Exclusion Criteria:

1. History of knee joint surgery within the past year
2. Presence of knee pain due to other causes, or conditions that affect the knee joint or impact its function (including but not limited to: transient synovitis, bone tuberculosis, bone tumors, acute traumatic arthritis, suppurative arthritis, rheumatoid arthritis, metabolic bone diseases, psoriatic arthritis, gouty arthritis, bone necrosis, ankylosing spondylitis, or active infections)
3. Presence of chronic knee pain caused by other reasons (such as post-herpetic neuralgia, osteoporosis, etc.)
4. Contraindications for shockwave therapy, such as deep venous thrombosis in the lower extremities, bleeding disorders or coagulation dysfunction, pregnancy, cognitive dysfunction, etc.
5. Presence of cancerous tumors, severe bronchiectasis, acute suppurative inflammation, high fever, active pulmonary tuberculosis, heart failure, severe anemia, cerebrovascular diseases, or the presence of a cardiac pacemaker implanted in the body
6. Inability to participate in the trial due to other health issues, such as sudden severe trauma, sudden severe infectious diseases, etc.

Where it's running

• 中山大学孙逸仙纪念医院
  Guangzhou, Guangdong, China Recruiting
• 中山大学孙逸仙纪念医院
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: 松坚 ke, 学士
• Email: songjian112626@163.com
• Phone: 86-020-81332732

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• One-Finger Technique to identify the left upper ureter during para-aortic lymphadenectomy

  This study tests a new surgical method to help surgeons find the left upper ureter during open para-aortic lymphadenectomy in women with gynecologic cancers.

  Recruiting Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07895212

• MRG003 added to ongoing treatment after progression in EGFR-positive advanced thyroid cancer

  In this study, researchers test whether adding MRG003 to a patient’s current thyroid cancer treatment can shrink tumors for those whose cancer initially responded but later progressed.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07874321

• Reducing Endotoxin Burden in Septic Shock Patients on CRRT with the oXiris Filter

  This trial tests whether using the oXiris hemofilter during continuous kidney replacement helps lower endotoxin levels in adults with septic shock who need CRRT.

  Recruiting Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07807410

• First-line combo therapy with anlotinib, benmelstobart, and HAIC for unresectable HCC

  This study tests whether adding benmelstobart and hepatic arterial infusion chemotherapy to anlotinib can help people with unresectable hepatocellular carcinoma respond to treatment as a first line.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07806292

• Culmerciclib with endocrine therapy before surgery for early HER2-negative hormone receptor-positive breast cancer

  This trial tests whether adding culmerciclib to an aromatase inhibitor before surgery helps women with certain early breast cancers better shrink tumors than an aromatase inhibitor alone.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07796880

• Optical surface guidance for head and neck radiotherapy with open-face mask

  This trial tests whether using optical surface guidance with an open-face mask during radiotherapy for head and neck cancer improves positioning and reduces movement compared with the standard closed mask approach.

  Recruiting Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07726407

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.